预约演示
更新于：2025-03-01
Doxylamine Succinate
琥珀酸多西拉敏
更新于：2025-03-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28N2O5 |
InChIKeyKBAUFVUYFNWQFM-UHFFFAOYSA-N |
CAS号562-10-7 |
关联
14
项与 琥珀酸多西拉敏 相关的临床试验CTRI/2024/08/072939
A Randomized Comparative Study of Sharbat Tamarhindi Versus Doxylamine Succinate in Emesis Gravidarum (Qay-al-haml) - NIL
CTIS2023-505144-19-00
A prospective, multicentre open-label clinical trial to evaluate the efficacy of the fixed-dose combination of Doxylamine and Pyridoxine 10/10 mg modified-release capsules on the quality of life of pregnant women presenting with nausea and vomiting of pregnancy (NVP). - RES-6131-C1
NCT06259747
Potential Therapeutic Implications of Acutaping on Nausea and Vomiting During Pregnancy
100 项与 琥珀酸多西拉敏 相关的临床结果
登录后查看更多信息
100 项与 琥珀酸多西拉敏 相关的转化医学
登录后查看更多信息
100 项与 琥珀酸多西拉敏 相关的专利（医药）
登录后查看更多信息
1,142
项与 琥珀酸多西拉敏 相关的文献（医药）2025-01-01CANADIAN FAMILY PHYSICIAN
Changes in doxylamine-pyridoxine dispensation in Ontario following media attention
Article
作者: Persaud, Nav ; Yazdani, Setayesh ; Chu, Cherry ; Tadrous, Mina ; Tharmarajah, Shenthuraan ; Chaudhry, Shanzeh
OBJECTIVE:
To understand the possible association between media coverage and changes in the dispensation of doxylamine-pyridoxine in Canada.
DESIGN:
Cross-sectional time-series analysis using data from the IQVIA CompuScript database.
SETTING:
Ten Canadian provinces.
PARTICIPANTS:
Family physicians, general practitioners, and obstetrician-gynecologists.
MAIN OUTCOME MEASURES:
Data on the estimated total volume of doxylamine-pyridoxine prescriptions dispensed by retail pharmacists in Ontario and across Canada between July 2016 and May 2022 were used for a time-series analysis. Birth data obtained from Statistics Canada were used to adjust for pregnancy rates. Finally, the possible impact of media coverage in January 2018 on doxylamine-pyridoxine use was assessed with interventional autoregressive integrated moving average modelling, and dispensation rates of doxylamine-pyridoxine were reported overall and by prescriber specialty.
RESULTS:
Doxylamine-pyridoxine dispensation decreased by 1.2% (P=.015) overall in Ontario but did not change significantly (P=.064) across the rest of Canada. Out of 619,720 total doxylamine-pyridoxine prescriptions dispensed, 391,722 (63.2%) prescriptions were written by family physicians or general practitioners in Ontario, and there was a decline of 2.4% (P=.010) in the dispensation of doxylamine-pyridoxine based on prescriptions written by this group that lasted for 6 months before returning to previous dispensation rates. There was no significant change in the dispensation of doxylamine-pyridoxine based on prescriptions written by obstetrician-gynecologists (decline of 0.5%, P=.235) in Ontario.
CONCLUSION:
Despite nationwide media attention questioning the efficacy of doxylamine-pyridoxine in early 2018, trends in dispensation rates of doxylamine-pyridoxine were only modestly affected and only in Ontario. Within Ontario, a small but significant reduction in doxylamine-pyridoxine dispensations was noted based on prescriptions from family physicians or general practitioners but not based on those written by obstetrician-gynecologists. Factors associated with the ongoing use of doxylamine-pyridoxine despite evidence of lack of benefit require further research.
2025-01-01WATER RESEARCH
Unexpected increase in microalgal removal of doxylamine induced by bicarbonate addition: synergistic chem-/bio-degradation mechanisms
Article
作者: Xiong, Jiu-Qiang ; Yang, Yushuang ; Jeon, Byong-Hun ; Gong, Yufeng ; Hu, Zhen-Hu ; Zhang, Xiaona ; Liang, Ying ; Qi, Xin
Microalgae-based approaches serve as promising methods for the remediation of pharmaceutical contaminants (PCs) compared to conventional wastewater treatment processes. However, how to decrease hydraulic retention times of the microalgal system currently has been one of the main bottlenecks. This study constructed an unexpected synergistic extra-chemical/intra-biological degradation system by adding 5.95 mM bicarbonate to the microalgal system, which achieved complete removal (100%) of a representative PC, doxylamine (DOX) in 96 h, compared to that 192 h in the control. Removal capacities and mass balance analyses demonstrated that biodegradation rate per unit microalgal density was significantly increased by 207%. Further analyses using transcriptomic, enzymatic inhibiting tests, and high-resolution mass spectrometry revealed that after addition of bicarbonate for metabolism of DOX, a hydrolase (CYP97C1) and a primary amine oxidase (TynA) can transform DOX into doxylamine N-oxide and an intermediate (C15H17NO2) with a m/z of 244.1335. Meanwhile, bicarbonate reacted with microalgae-excreted hydrogen peroxide to form more oxidative radicals such as superoxide and hydroxyl radicals extracellularly, which promised the extracellular degradation of DOX according to the oxidative radical inhibiting tests. Further investigation showed addiing bicarbonate to the microalgal system improved the removal rate of 17 PCs by up to 500.8%. Therefore, this study not only developed an approach to enhance treatment efficiencies of diverse PCs by microalgae within a shorter time, but also carried unique mechanistic insights into the underlying principles.
2024-12-01Computational and structural biotechnology journal
Explainable machine learning model for identifying key gut microbes and metabolites biomarkers associated with myasthenia gravis
Article
作者: Lu, Chi-Jie ; Chiu, Hou-Chang ; Liu, Tzu-Chi ; Chang, Che-Cheng ; Lin, Wei-Ning
Diagnostic markers for myasthenia gravis (MG) are limited; thus, innovative approaches are required for supportive diagnosis and personalized care. Gut microbes are associated with MG pathogenesis; however, few studies have adopted machine learning (ML) to identify the associations among MG, gut microbiota, and metabolites. In this study, we developed an explainable ML model to predict biomarkers for MG diagnosis. We enrolled 19 MG patients and 10 non-MG individuals. Stool samples were collected and microbiome assessment was performed using 16S rRNA sequencing. Untargeted metabolic profiling was conducted to identify fecal amplicon significant variants (ASVs) and metabolites. We developed an explainable ML model in which the top ASVs and metabolites are combined to identify the best predictive performance. This model uses the SHapley Additive exPlanations method to generate both global and personalized explanations. Fecal microbe-metabolite composition differed significantly between groups. The key bacterial families were Lachnospiraceae and Ruminococcaceae, and the top three features were Lachnospiraceae, inosine, and methylhistidine. An ML model trained with the top 1 % ASVs and top 15 % metabolites combined outperformed all other models. Personalized explanations revealed different patterns of microbe-metabolite contributions in patients with MG. The integration of the microbiota-metabolite features and the development of an explainable ML framework can accurately identify MG and provide personalized explanations, revealing the associations between gut microbiota, metabolites, and MG. An online calculator employing this algorithm was developed that provides a streamlined interface for MG diagnosis screening and conducting personalized evaluations.
100 项与 琥珀酸多西拉敏 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 超敏反应 | 美国 | 1948-04-07 | |
| 早孕反应 | 美国 | 1948-04-07 | |
| 入睡和睡眠障碍 | 美国 | 1948-04-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 妊娠剧吐 | 临床3期 | 加拿大 | 2006-02-01 | |
| 恶心 | 临床3期 | 加拿大 | 2006-02-01 | |
| 怀孕 | 临床3期 | 加拿大 | 2006-02-01 | |
| 呕吐 | 临床3期 | 加拿大 | 2006-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 20 | 窪窪夢範簾網蓋鹽製衊(鑰鬱齋襯鑰鬱網鹽廠餘) = 壓獵選襯獵觸壓鑰夢顧 蓋築簾範襯遞窪製選繭 (獵憲鑰壓構構窪鑰遞積, 鬱夢廠簾淵鑰壓鹽窪構 ~ 範衊遞窪齋獵窪遞醖糧) | - | 2013-09-26 | |||
Intravenous arm (Intravenous Arm) | 壓衊夢襯餘襯簾齋鹽願(壓鑰觸鏇憲鬱獵糧遞醖) = 範範夢齋齋鹽範網壓築 顧憲選築遞獵夢築壓襯 (鏇襯襯廠齋築鏇積壓艱, 艱鹹獵憲鏇簾衊廠淵繭 ~ 鬱鹽衊願鏇觸襯簾遞鹽) 更多 | ||||||
临床1期 | 41 | (Subjects Aged 2-5 Years) | 鏇餘選夢選艱艱醖願製(壓網獵夢築衊淵積願選) = 淵製艱鑰願艱獵願遞齋 觸繭網壓範鏇遞製鹹顧 (鬱願願壓觸壓築選衊糧, 製繭鹹蓋齋糧鏇糧淵衊 ~ 願齋築齋齋積鬱範窪築) 更多 | - | 2013-01-25 | ||
(Subjects Aged 6-11 Years) | 鏇餘選夢選艱艱醖願製(壓網獵夢築衊淵積願選) = 獵築艱範憲積膚餘餘鏇 觸繭網壓範鏇遞製鹹顧 (鬱願願壓觸壓築選衊糧, 鏇獵艱醖積遞憲鏇顧糧 ~ 壓夢獵繭膚壓築積觸簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用